Home/ Stocks/ EXEL

Exelixis Inc

EXEL XNAS

$48.16 +1.95 (+4.22%) ▲ 15-min delayed

Open

$46.59

High

$48.17

Low

$46.46

Volume

2.18M

Market Cap

$12.11B

About Exelixis Inc

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 1.1K Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2027	$610.81M	$210.47M	$0.81
Q3 2026	$597.75M	$193.58M	$0.72
Q2 2026	$568.26M	$184.85M	$0.68
Q1 2026	$555.45M	$159.62M	$0.57

Related Market News

No specific coverage for EXEL yet. Check out our latest market news or earnings calendar.

Get EXEL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Exelixis Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.